Objective. To assess whether a nonparticulate steroid (dexamethasone, 10 mg) is less clinically effective than the particulate steroids (triamcinolone, 80 mg; betamethasone, 12 mg) in lumbar transforaminal epidural steroid injections (TFESIs) in subjects with radicular pain with or without radiculopathy.
Introduction
Lumbar transforaminal epidural steroid injections (TFESIs) have been shown to be effective in diminishing pain and improving physical functioning in patients suffering from radicular pain with or without radiculopathy bs_bs_banner Pain Medicine 2013; 14: 1650-1657 Wiley Periodicals, Inc. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . A surgical sparing effect [9, 10] has been demonstrated, and TFESIs have been shown to be cost-effective in specific circumstances [5] . The corticosteroid preparation used in these procedures has historically been a particulate steroid-methylprednisolone, triamcinolone, or betamethasone. The explanatory trial that most convincingly demonstrates the efficacy of TFESIs used triamcinolone as the steroid preparation [12] .
Catastrophic complications following lumbar TFESI have been reported, with infarctions of the spinal cord leading to paralysis. Thirteen case reports have described acute paraplegia due to spinal cord infarction following lumbar TFESIs at all levels between L1 and S1 [15] [16] [17] [18] [19] [20] [21] [22] [23] . All of these complications have occurred with particulate steroids. The proposed mechanism of these catastrophic complications is embolization of a medullary artery (artery of Adamkiewicz), compromising the arterial supply of the lower thoracic cord and conus medullaris. Studies by Derby and Benzon have demonstrated that methylprednisolone, triamcinolone, and betamethasone all contain either particles or aggregates that can act as embolic material at the arteriolar level [24, 25] . Dexamethasone, however, contains no particles exceeding the diameter of a red blood cell and will not act as an embolic agent. It is being adopted in many centers as the corticosteroid of choice for TFESIs; no catastrophic complications have been reported using dexamethasone.
While the greater safety profile of dexamethasone in TFESIs is not in dispute, there remains concern that the efficacy of dexamethasone may not match that of the particulate corticosteroids. The pragmatic studies of Dreyfuss [26] and Lee [27] showed a nonsignificant trend toward greater efficacy in cervical TFESIs with triamcinolone vs dexamethasone. Park [28] demonstrated a significantly greater improvement in pain, but not function, after lumbar TFESI with triamcinolone in comparison with dexamethasone.
As the available studies are not conclusive, a large randomized controlled trial might be demanded to establish the noninferiority of dexamethasone vs particulate steroids. A noninferiority randomized controlled trial would require a large study population at significant cost and may expose patients to unacceptable risks. An alternative inquiry would be a retrospective analysis of an outcomes database containing large numbers of lumbar TFESIs performed with either particulate steroids or dexamethasone. This would allow inspection for trends in comparative effectiveness in a clinical practice setting and provide the basis for power calculations if a formal noninferiority trial should prove justified. The current study interrogated such a database to retrospectively assess for noninferiority of the nonparticulate steroid dexamethasone relative to the particulate steroid preparations, triamcinolone or betamethasone, in patients with lumbar radicular pain with or without radiculopathy.
Materials and Methods
The study was approved by the local Institutional Review Board and complied with all Health Insurance Portability and Accountability Act requirements.
Patient Population
The study cohort included 3,645 TFESIs performed in 2,634 patients between January 2006 and February 2011 at the L4-5, L5-S1, or S1 foraminal levels using the steroid dosages noted below as treatment for radicular pain with or without radiculopathy. The study cohort included patients receiving more than one injection when there were at least 2 months between injections. The anatomic lesions causal of radicular pain included both disc herniations and fixed lateral recess or foraminal stenosis. Immediately prior to the procedure, patients completed two outcome measures: the Roland-Morris disability questionnaire (R-M, 23-point Deyo modification [29] that addresses functional disability due to radicular pain) and a pain numerical rating scale (NRS) score (0-10, where 0 was no pain and 10 the worst pain imaginable).
Procedural Technique
TFESIs were performed in accord with the guidelines of the International Spine Intervention Society [30] Procedural techniques have been previously reported [13] . Over the study period, the corticosteroids used included triamcinolone acetonide (Kenalog, 80 mg in 2 mL, BristolMyers Squibb, New York, NY, USA), betamethasone sodium phosphate/betamethasone acetate (Celestone, 12 mg in 2 mL, American Regent, Inc., Shirley, NY, USA), or preservative-free dexamethasone sodium phosphate (10 mg in 1 mL, APP Pharmaceuticals, LLC, Lake Zurich, IL, USA). Betamethasone was the preferred agent from 2006 to 2010; triamcinolone was used when betamethasone was not commercially available. In response to the safety concerns noted above, dexamethasone became the preferred corticosteroid for all lumbar TFESIs after October 2010.
Clinical Follow-Up Data
All subject data were entered into an SAS database (SAS Institute, Cary, NC, USA). An independent paramedical assessor obtained follow-up R-M and NRS data via telephone call at 2 weeks and 2 months postprocedure. At least three attempts were made to contact each subject at each time point.
Statistical Analysis: Overview of Noninferiority Analysis
Response difference was used to quantify the clinical effectiveness of the nonparticulate steroid dexamethasone relative to the particulate steroids. This metric is the difference in the response rates between these two groups, with associated confidence intervals (CIs). Response rates in both NRS and R-M scores were used for the primary analysis. The principles of a noninferiority analysis were utilized; Figure 1 illustrates this analytical approach [31] .
In traditional superiority testing, the null hypothesis would state there is no difference in the response rates between the two groups. Failure to reject this null hypothesis could imply that the two treatments are equally effective or, more importantly, that there was simply insufficient statistical evidence to reject the null, a type II error [32] . Noninferiority analyses address the second limitation by reformulating the statistical hypotheses to formally test for noninferiority and superiority. In instances where the responses are expected to be similar between two treatments (a candidate treatment [dexamethasone] relative to a standard treatment [particulate steroids]), one would expect the response difference to be close to zero. A "limit of noninferiority," δ, is used to determine how inferior a candidate treatment could be and still be considered noninferior. This study used a limit of noninferiority of 10%, or −0.1. To illustrate, consider a scenario where nonparticulate and particulate steroid response rates were both 50% (response difference = 0.5-0.5 = 0); there would be support for noninferiority as the response difference was greater than the limit of noninferiority (0.0 > −0.1). If the nonparticulate response rate were lower, for example 30%, then the response difference (0.3-0.5 = −0.2) would be too large to determine noninferiority.
The formal analysis requires the use of CIs to account for statistical variation. If the estimated CI for the candidate treatment excludes the limit of noninferiority, one would reject the null hypothesis of inferiority in favor of an alternative hypothesis of noninferiority (case B in Figure 1) . Sometimes, the CI will exclude 0.0 and indicate that candidate treatment is superior to the standard treatment (case C in Figure 1 ). When the CI includes the limit of noninferiority, the null hypothesis is not rejected, and the statistical interpretation is that the candidate treatment has not demonstrated statistical evidence to be considered noninferior (noninferiority not demonstrated, case A in Figure 1 ). Estimation of the response difference and associated CIs, which is essential to the interpretation of the data in this noninferiority framework, required special statistical considerations to account for the multiple treatments in some patients. As a result of the modeling process, the reported response differences and differences in means will vary slightly from the numerical difference in steroid group response rates or mean scores reported in the tables.
Statistical Analysis Plan
Statistical analyses were conducted using SAS version 9.2 (SAS Institute). Continuous scores and categorical response outcomes were evaluated. The successful categorical responses (responders) were defined as reduction in pain by at least 50%, or 0/10 pain at the time of measurement. Successful functional response was a reduction in R-M score by 40% or more, which is the minimal clinically important difference [33] .
Preliminary analyses compared demographics and baseline NRS and R-M scores among the three types of steroids using one-way analysis of variance models. When overall differences were seen, pairwise comparisons of steroid types were conducted using t-tests with Bonferroni corrections for multiple testing. For the primary outcomes, generalized estimating equations were used to test for associations of steroid type with 2-week and 2-month NRS or R-M response, and to accommodate Figure 1 Illustration of noninferiority analysis. In this study, the candidate treatment, dexamethasone, is being compared with the standard treatment, the particulate steroids. At the 0 line, there is no difference in response rates between dexamethasone and the particulate steroids. The limit of noninferiority (δ) is set at −10%. In case A, the 95% confidence interval includes the limit of noninferiority, and noninferiority cannot be demonstrated. Note that with broad confidence intervals, this may occur even when the response difference is positive for the candidate treatment. In case B, the confidence interval excludes the limit of noninferiority, and noninferiority is demonstrated. In case C the confidence interval is above 0, and the candidate treatment is superior. multiple procedures within subjects. Steroid type was considered as a predictor of 40% or 50% binary response in models adjusted for age, gender, preprocedure pain or R-M score, and duration of pain (0-3 months vs >3 months). The proportion of patients for each steroid type who achieved complete pain relief and the proportion of patients who required additional injections within 6 months were calculated.
Subgroup analyses were also performed in an attempt to remove potential bias introduced by the chronology of the steroid use, i.e., the nonparticulate steroid dexamethasone was exclusively used in more recent cases. The cases of the senior author (T. M., 37% of all injections among 11 operators) were analyzed on the hypothesis that in this cohort, injection technique would be most consistent over the study period. Injections at the S1 foramen (31.7% of all injections) were also separately analyzed as there was likely to be the least technical variation at this level. More infraneural needle placements have been utilized in this practice at the L4 and L5 levels following the description of the intraforaminal location of the artery of Adamkiewicz in 2010 [34] . Finally, patients with less than 3 months of pain were evaluated as they have been shown in a prior study to be most responsive to TFESIs [13] .
Noninferiority tests of the nonparticulate steroid dexamethasone compared with the particulate steroids were performed. The margin of noninferiority of the risk difference in ≤50% (NRS) or ≤40% (R-M) outcomes was −0.1, meaning that CIs on the response difference excluding −0.1 were considered to indicate that the nonparticulate steroid was noninferior. The −0.1 margin of noninferiority indicates at most a 10% decrease in favorable response in the nonparticulate. For the continuous outcomes using the NRS and R-M mean scores, noninferiority tests of steroid type used 0.3 and 1.0 as the difference bounds, respectively. As lower mean NRS and R-M scores indicate greater improvement, the difference bounds are positive.
Results
A total of 3,645 lumbar TFESIs were performed on 2,634 patients using dexamethasone, triamcinolone, or betamethasone (Table 1) . There were demographic differences in the groups that led to the use of these factors as covariates in the linear regression model, lessening any confounding effect. In the entire study cohort, 42.5% of TFESIs resulted in ≥50% improvement in NRS at 2 weeks and 45.1% had such improvement at 2 months. In the entire cohort, 33.1% of TFESI procedures demonstrated ≥40% improvement in R-M at 2 weeks; 39.8% had such improvement at 2 months follow-up. 
Dexamethasone vs

Categorical Outcomes: Subgroup Analysis
The noninferiority of dexamethasone relative to the particulate steroids persisted in the subgroup analyses at 2 months (Table 3 ). In patients undergoing S1 injections, dexamethasone was demonstrated to be noninferior to the particulate steroids in pain relief ( 
Proportion of Patients Achieving Complete Pain Relief
There was no difference among the steroid types in the proportion of patients who achieved complete pain relief at 2 months follow-up. The proportion of patients with no pain at 2 months follow-up was 16.4% (13.9, 19. 
Dexamethasone vs Particulate Steroids: Continuous Outcomes
The mean NRS and R-M scores prior to TFESIs were indistinguishable for the three steroid types (Table 1) , when compared with the scores for procedures using triamcinolone or betamethasone (Table 2) . Mean 2 month pain (NRS) and functional disability (R-M) scores for procedures employing dexamethasone were superior, i.e., significantly lower, when compared with scores of patients receiving triamcinolone or betamethasone, although the absolute differences were small (NRS difference −0.57
Requirement for Repeat Injections
The study cohort included patients who underwent repeat injections. As a possible measure of the durability of effect, the proportion of patients who underwent repeat injections within 6 months of the index injection was stratified by steroid type. Repeat injections were performed within 6 months in 9.9% (8.1, 11.7) of patients receiving triamcinolone, 6.0% (4.9, 7.1) of patients receiving betamethasone, and 4.2% (1.5, 6.9) of patients receiving dexamethasone.
Analysis of Missing Data
There were many patients lost to follow-up; this largely reflects inadequate institutional resources allocated for follow-up telephone calls. From the initial cohort of 3,645 injection procedures, follow-up data were available for 2,958 injections (81.2%) at 2 weeks and 2,175 injections (60%) at 2 months. Comparisons of demographics and clinical characteristics between subjects lost to follow-up at 2 months and subjects successfully contacted at 2 months revealed that those missing were more likely to be male (odds ratio [OR] = 1.27), younger (age OR = 0.991), have higher preprocedure pain (OR = 1.109), and have pain of <3 months duration (OR = 1.317) (all P values <0.001). As all of these factors predict a favorable response to TFESI in the sample, these associations are unlikely to inflate the response rates [13] .
Discussion
This retrospective observational study demonstrates the noninferiority of dexamethasone (10 mg) relative to triamcinolone (80 mg) or betamethasone (12 mg) in providing pain relief and functional recovery at 2 months follow-up of lumbar TFESIs performed for radicular pain with or without radiculopathy. Noninferiority of dexamethasone relative to the particulate steroids was demonstrated with categorical outcomes. With continuous outcomes, dexamethasone was superior to the particulate steroids in pain relief and functional recovery at 2 months following TFESIs. The noninferiority of dexamethasone was also confirmed in subgroup analyses performed to address possible bias introduced by the use of dexamethasone in more recent cases. There was no difference in the proportion of patients achieving complete pain relief with dexamethasone vs either particulate steroid. Repeat injections within 6 months were more frequent with the particulate steroids than with dexamethasone. Given the greater safety profile of dexamethasone, these findings argue strongly for the use of dexamethasone in lumbar TFESIs.
Several investigators have previously addressed the question of the relative efficacy of nonparticulate vs particulate corticosteroids in TFESIs. In a randomized controlled trial by Dreyfuss, 30 patients with radicular pain and correlative single-level neural compression on imaging underwent cervical TFESIs using either 12.5 mg of dexamethasone or 60 mg of triamcinolone [26] . The efficacy of dexamethasone and triamcinolone was compared using the proportion of responders who achieved either complete or 50% pain relief as the primary outcome with a secondary functional outcome, measured 4 weeks after the injection. In this small trial, there was no significant difference in efficacy; there was a trend toward greater efficacy with triamcinolone.
The randomized control trial of Park [28] included 106 patients with lumbar radicular pain and correlative imaging who received either 7.5 mg of dexamethasone or 40 mg of triamcinolone by TFESI. One month post injection, pain was assessed by visual analog scale (VAS) score and the McGill pain questionnaire; functional improvement was measured by the Oswestry disability index. Using mean values of continuous data, pain measured by VAS was improved significantly more with triamcinolone then dexamethasone; this was not corroborated by the McGill pain questionnaire. Neither agent resulted in a statistically significant functional improvement, nor was there a difference between the agents. Using categorical data, the proportion of subjects achieving a 50% VAS reduction favored triamcinolone over dexamethasone, without statistical significance.
In a retrospective trial by Lee [27] , 159 patients with cervical radiculopathy and correlative imaging underwent cervical TFESIs using 40 mg of triamcinolone or 10 mg of dexamethasone. Ninety-seven patients received triamcinolone injections, followed by 62 patients injected with dexamethasone. On short-term (mean = 15.8 days) follow-up, pain improvement was assessed using a fivepoint scale with outcomes categorized as effective (no pain, much improved pain) or ineffective. Cervical TFESI were effective in 76.1% of all patients; there was a nonsignificant trend favoring triamcinolone.
The current study conclusions may initially seem disparate from the literature, but on careful inspection they are coincident. The pragmatic studies of Dreyfuss, Lee, and Park measured outcomes at 1 month or less after injection and demonstrated slightly greater efficacy in pain relief with triamcinolone vs dexamethasone in TFESIs. This greater efficacy only reached statistical significance in the Park study using continuous, not categorical data. The current study outcomes at 2 weeks show a nonsignificant trend for greater effectiveness of the particulate steroids, similar to the earlier studies. At 2 months, however, all significant differences in effectiveness, especially in functional improvement, favor dexamethasone. Continuous outcomes show significantly lower mean pain and disability scores in patients receiving dexamethasone. The pharmacokinetics of corticosteroid bioavailability following deposition in the epidural space are unstudied. Further basic research is necessary to understand the pharmacological underpinning of these clinical observations.
It is noteworthy that the steroid doses utilized in the current study population were not equivalent in antiinflammatory effect. Betamethasone is thought to have a slightly greater anti-inflammatory effect than dexamethasone per milligram; both of these agents are approximately fivefold more potent than triamcinolone per milligram [35] . In the study cohort, therefore, relatively more anti-inflammatory agent was delivered via either particulate steroid, especially triamcinolone, when compared with dexamethasone. Despite this, there was no evidence of diminished effectiveness of dexamethasone; where differences were detected in 2 months outcomes, they favored dexamethasone. Dexamethasone was used in the one available dose ranging trial for TFESIs; this showed no difference in efficacy for dexamethasone doses of 4 mg, 8 mg, or 12 mg [36] . The ideal dose of dexamethasone may be lower than the 10 mg used in this current study.
The study has several weaknesses, some of which have been discussed above. This was a retrospective study, with an uncontrolled temporal variable in the use of the corticosteroid agents. Subgroup analyses were performed to attempt to control for the more recent use of dexamethasone, and these analyses support the noninferiority of dexamethasone. There were a significant number of patients lost to follow-up due to personnel limitations. These data may not be missing at random and could confound the analysis. Despite these shortcomings, the study assesses, in the context of routine clinical practice, larger numbers of procedures than in any of the available pragmatic trials.
Conclusion
This retrospective observational study showed no evidence that the nonparticulate steroid dexamethasone was less effective than the particulate steroids triamcinolone or betamethasone in lumbar TFESIs performed at the L4-5, L5-S1, or S1 foramina for radicular pain with or without radiculopathy. Where differences in pain relief and functional outcomes at 2 months were seen, they favored dexamethasone. These findings, in concert with the greater safety profile of dexamethasone, suggest that dexamethasone should be used as the preferred agent in lumbar TFESIs.
